Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 76

1.

EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44.

Pályi-Krekk Z, Barok M, Kovács T, Saya H, Nagano O, Szöllosi J, Nagy P.

Cancer Lett. 2008 May 18;263(2):231-42. doi: 10.1016/j.canlet.2008.01.014. Epub 2008 Feb 13.

PMID:
18276068
[PubMed - indexed for MEDLINE]
2.

Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.

Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, Poghosyan Z, Nicholson RI, Barrett-Lee P, Gee J.

BMC Cancer. 2012 Oct 6;12:458. doi: 10.1186/1471-2407-12-458.

PMID:
23039365
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.

Pályi-Krekk Z, Barok M, Isola J, Tammi M, Szöllosi J, Nagy P.

Eur J Cancer. 2007 Nov;43(16):2423-33.

PMID:
17911008
[PubMed - indexed for MEDLINE]
4.

Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration.

Bourguignon LY, Gilad E, Peyrollier K.

J Biol Chem. 2007 Jul 6;282(27):19426-41. Epub 2007 May 10.

PMID:
17493932
[PubMed - indexed for MEDLINE]
Free Article
5.

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.

Exp Cell Res. 2005 Apr 1;304(2):604-19. Epub 2005 Jan 21.

PMID:
15748904
[PubMed - indexed for MEDLINE]
6.

Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.

Friedländer E, Arndt-Jovin DJ, Nagy P, Jovin TM, Szöllosi J, Vereb G.

Cytometry A. 2005 Oct;67(2):161-71.

PMID:
16163699
[PubMed - indexed for MEDLINE]
Free Article
7.

Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.

Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G.

Cytometry A. 2011 Sep;79(9):684-93. doi: 10.1002/cyto.a.21107. Epub 2011 Jul 22.

PMID:
21786419
[PubMed - indexed for MEDLINE]
Free Article
8.
9.

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.

Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, Arteaga CL.

Clin Cancer Res. 2007 Aug 15;13(16):4909-19.

PMID:
17699871
[PubMed - indexed for MEDLINE]
Free Article
10.

ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.

Cornelissen B, Darbar S, Hernandez R, Kersemans V, Tullis I, Barber PR, Smart S, Vojnovic B, Reilly R, Vallis KA.

J Nucl Med. 2011 May;52(5):776-83. doi: 10.2967/jnumed.110.084392. Epub 2011 Apr 15.

PMID:
21498540
[PubMed - indexed for MEDLINE]
Free Article
11.

V3 versican isoform alters the behavior of human melanoma cells by interfering with CD44/ErbB-dependent signaling.

Hernández D, Miquel-Serra L, Docampo MJ, Marco-Ramell A, Cabrera J, Fabra A, Bassols A.

J Biol Chem. 2011 Jan 14;286(2):1475-85. doi: 10.1074/jbc.M110.127522. Epub 2010 Nov 15.

PMID:
21078678
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.

Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G.

Immunol Lett. 2006 Apr 15;104(1-2):146-55. Epub 2005 Dec 12.

PMID:
16384610
[PubMed - indexed for MEDLINE]
13.

EGF receptor modifies cellular responses to hyaluronan in glioblastoma cell lines.

Tsatas D, Kanagasundaram V, Kaye A, Novak U.

J Clin Neurosci. 2002 May;9(3):282-8.

PMID:
12093135
[PubMed - indexed for MEDLINE]
14.

Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer.

Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J.

Mol Cancer Ther. 2004 Dec;3(12):1585-92.

PMID:
15634652
[PubMed - indexed for MEDLINE]
Free Article
15.

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.

Barok M, Isola J, Pályi-Krekk Z, Nagy P, Juhász I, Vereb G, Kauraniemi P, Kapanen A, Tanner M, Vereb G, Szöllösi J.

Mol Cancer Ther. 2007 Jul;6(7):2065-72.

PMID:
17620435
[PubMed - indexed for MEDLINE]
Free Article
16.

The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.

Motoyama AB, Hynes NE, Lane HA.

Cancer Res. 2002 Jun 1;62(11):3151-8.

PMID:
12036928
[PubMed - indexed for MEDLINE]
Free Article
17.

177Lu-Labeled humanized monoclonal antibody against human epidermal growth factor receptor 2.

Chopra A.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2008 Nov 17 [updated 2008 Dec 17].

PMID:
20641866
[PubMed]
Books & Documents
18.

Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.

Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M.

Cancer Res. 2009 Dec 15;69(24):9330-6. doi: 10.1158/0008-5472.CAN-08-4597. Epub .

PMID:
19934333
[PubMed - indexed for MEDLINE]
Free Article
20.

Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

Nagy P, Friedländer E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM.

Cancer Res. 2005 Jan 15;65(2):473-82.

PMID:
15695389
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk